Immune Checkpoint Inhibitors | Special Topics | Trends and Market Dynamics – Multi Indication | G7 | 2021

launch Related Market Assessment Reports

• Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  March 2023

  Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors; it is characterized by muscle…

• Unipolar Depression – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  February 2023

  Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective…

• Schizophrenia – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)

  February 2023

  Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…

• Axial Spondyloarthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis: Ankylosing Spondylitis (US)

  February 2023

  Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…

• Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast

  December 2022

  Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…